

References

- Agathe Pardon, Vincent Audard, Sophie Caillard, Bruno Moulin, Dominique Desvaux, Bouteina Bentaarit, Philippe Remy, Dil Sahali, Franc,oise Roudot-Thoraval, Philippe Lang and Philippe Grimbert. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. *Nephrol Dial Transplant* (2006) 21: 1053–1059
- Alak AM. Measurement of tacrolimus(FK506)and its metabolites; a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. *Ther DRUG* 1997; 19:338-51.
- Alexopoulos E; Papagianni A; Tsamelashvili M; Leontsini M; Memmos D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. *Nephrol Dial Transplant*. 2006 Nov; 21(11):3127-32.
- Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. *Am J Transplant* 2003; 3:1211-1215.
- Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS. Risk factors for chronic rejection in renal allograft recipients. *Transplantation*. 1993 Apr; 55(4):752-6.

- Andresdottir MB; Assmann KJ; Koene RA; Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. *Am J Kidney Dis* 1998 Oct; 32(4):582-8.
- Andresdottir MB; Assmann KJ; Koene RA; Wetzels JF. Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. *Am J Kidney Dis* 1998 Oct; 32(4):582-8.
- Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis. Natural history and response to therapy. *Am J Med* 1992; 92: 375–383.
- B.H. Özdemir, F.N. Özdemir, S. Sezer, T. Çolak, and M. Haberal. De Novo Glomerulonephritis in Renal Allografts with Hepatitis C Virus Infection. *Transplantation Proceedings* 2006, 38, 492–495.
- Barr RG, Seliger S, Apple GB. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. *Nephrol Dial Transplant* 2003; 18:2039-2046.
- Barratt J; Feehally J. Treatment of IgA nephropathy. *Kidney Int.* 2006 Jun; 69(11):1934-8.
- Barsoum, R. The changing face of schistosomal glomerulopathy. *Kidney Int* 2004; 66:2472.

- Basse G; Ribes D; Kamar N; Mehrenberger M; Esposito L; Guitard J; Lavayssiere L; Oksman F; Durand D; Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. *Transplantation* 2005 Dec 15; 80(11):1560-4.
- Basse G; Ribes D; Kamar N; Mehrenberger M; Esposito L; Guitard J; Lavayssiere L; Oksman F; Durand D; Rostaing L. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. *Transplantation*. 2005 Dec 15; 80(11):1560-4.
- Beck LH Jr., D. Salant: Glomerular and Tubulointerstitial Diseases in Primary Care. *Prim Care*. 2008 Jun; 35(2):265-96.
- Bela Ivanyi, A primer on recurrent and de novo glomerulonephritis in renal allografts. *NATURE CLINICAL PRACTICE NEPHROLOGY* august 2008; 4 (8):446-457.
- Bennett W. Immunosuppression with mycophenolic acid: one size does not fit all. *J Am Soc Nephrol* 2003; 14:2414-2418.
- Berger BE; Vincenti F; Biava C; Amend WJ Jr; Feduska N; Salvatierra O Jr. De novo and recurrent membranous glomerulopathy following kidney transplantation. *Transplantation* 1983 Apr; 35(4):315-9.
- Berger J, Yaneva H, Nabarra B, Barbanel C. Recurrence of mesangial deposition of IgA after renal transplantation. *Kidney Int* 1975; 7: 232–241

- Berthoux F; El Deeb S; Mariat C; Diconne E; Laurent B; Thibaudin L. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. *Transplantation*. 2008 May 27; 85(10):1505-7.
- Bhalla V; Nast CC; Stollenwerk N; Tran S; Barba L; Kamil ES; Danovitch G; Adler SG. Recurrent and de novo diabetic nephropathy in renal allografts. *Transplantation*. 2003 Jan 15; 75(1):66-71.
- Bielmann D, Hönger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. *Am J Transplant*. 2007 Mar;7(3):626-32.
- Bodziak K, Hricik D. Minimizing the side effects of immunosuppression in kidney transplant recipients. *Transplantation* 2003; 8:160-165.
- Branten AJ; Vervoort G; Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. *Nephrol Dial Transplant* 2005 Apr; 20(4):707-11.
- Braun MC; Stablein DM; Hamiwka LA; Bell L; Bartosh SM; Strife CF. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. *J Am Soc Nephrol* 2005 Jul; 16(7):2225-33.

- Bray RA, Nolen JD, Larsen C, Pearson T, Newell KA, Kokko K, Guasch A, Tso P, Mendel JB, Gebel HM. Transplanting the highly sensitized patient: The emory algorithm. *Am J Transplant*. 2006 Oct; 6(10):2307-15.
- Brennan DC. Faith supported by reason: mechanistic support for the use of polyclonal antibodies in transplantation. *Transplantation* 2003; 75:577-582.
- Briganti E, Russ G, McNeil J, Atkins R, Chadban S. Risk of renal allograft loss from recurrent glomerulonephritis. *N Engl J Med* 2002; 347:103–109.
- Briggs J, Jones E: Recurrence of glomerulonephritis following renal transplantation. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. *Nephrol Dial Transplant* 1999; 14: 564–565.
- Broyer M, Selwood N, Brunner F. Recurrence of primary renal disease on kidney graft: a European pediatric experience. *J Am Soc Nephrol* 1992; 2 [Suppl 12]: S255–S257.
- Burdmann EA; Andoh TF; Yu L; Bennett WM. Cyclosporine nephrotoxicity. *Semin Nephrol* 2003 Sep;23(5):465-76.
- Busch GJ, Chavers BM, Gillingham KJ, et al: Chronic renal allograft rejection in the first 6 months post-transplantation. *Transplantation*, 1995 60:1413.

- Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. *Nephrol Dial Transplant*. 2004 Dec; 19(12):3144-9.
- Cai J, Terasaki PI, Anderson N, Lachmann N, Schönemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. *Transplantation*. 2009 Jul 27; 88(2):226-30.
- Cameron JS. Recurrent disease in renal allografts. *Kidney Int* 1993; 44 [Suppl 43]: S91–S94.
- Cameron JS. Recurrent primary disease and de novo nephritis following renal transplantation. *Pediatr Nephrol* 1991; 5:412–421.
- Canadian Organ Replacement Register: Treatment of End-Stage Organ Failure in Canada 1995 to 2004, Ottawa, Ontario, Canada, Canadian Institute for Health Information, 2006.
- Carpenter, CB. Immunosuppression in organ transplantation. *N Engl J Med* 1990; 322:1224.
- Cattran DC. Idiopathic membranous glomerulonephritis. *Kidney Int* 2001 May; 59(5):1983-94.
- Cecka JM, Cicciarella J, Mickey MR, Terasaki PI. Blood transfusions and HLA matching--an either/or situation in cadaveric renal transplantation. *Transplantation*. 1988 Jan; 45(1):81-6.

- Cecka JM. Results of more than 1000 recent living-unrelated donor transplants in the United States. *Transplant Proc* 1999; 31: 234.
- Cecka JM. The UNOS transplant registry. In Cecka JM, Terasaki PI, eds. *Clinical Transplants* 2001. Los Angeles: UCLA, 2002: 1–18.
- Chadban S: Glomerulonephritis recurrence in renal allograft. *J Am Soc Nephrol* 12:394-402, 2001.
- Chadban SJ, Atkins RC. Glomerulonephritis. *Lancet*. 2005 May 21-27; 365(9473):1797-806.
- Chandrakantan A; Ratanapanichkich P; Said M; Barker CV; Julian BA. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil. *Nephrol Dial Transplant* 2005 Jun; 20(6):1214-21.
- Cheigh JS, Mouradian J, Susin M et al. Kidney transplant nephrotic syndrome: Relationship between allograft histopathology and natural course. *Kidney Int* 1980; 18: 358–365
- Cheigh JS; Mouradian J; Susin M; Stubenbord WT; Tapia L; Riggio RR; Stenzel KH; Rubin AL. Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course. *Kidney Int* 1980 Sep;18(3):358-65.
- Cheong HI, Han HW, Park HW. Early recurrent nephritic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 2000; 15:78–81.

- Cho YW, Cecka JM. Cross-match tests. An analysis of UNOS data from 1991–2000. In Cecka JM, Terasaki PI, eds. *Clinical Transplants 2001*. Los Angeles: UCLA Tissue Typing Laboratory, 2002: 237–46.
- Choi MJ; Eustace JA; Gimenez LF; Atta MG; Scheel PJ; Sothinathan R; Briggs WA. Mycophenolate mofetil treatment for primary glomerular diseases. *Kidney Int* 2002 Mar; 61(3):1098-114.
- Choy B, Chan T, Lai K: Recurrent glomerulonephritis after kidney transplantation. *Am J Transplant* 2006 6: 2535–2542.
- Choy BY; Chan TM; Lai KN. Recurrent glomerulonephritis after kidney transplantation. *Am J Transplant*. 2006 Nov; 6(11):2535-42.
- Chun MJ; Korbet SM; Schwartz MM; Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. *J Am Soc Nephrol* 2004 Aug; 15(8):2169-77.
- Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. *Clin J Am Soc Nephrol*. 2008 May; 3(3):814-21.
- Conlon PJ, Lynn K, Winn MP et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. *Kidney Int* 1999; 56: 1863–1871.
- Cosio FG, Pelletier RP, Falkenhain ME, et al. Impact of acute rejection and early allograft function on renal allograft survival. *Transplantation* 1997; 63: 1611–15.

- Cosio FG, Sedmak DD, Henry ML et al. The high prevalence of severe early post-transplant renal allograft pathology in hepatitis C positive recipients. *Transplantation* 1996; 62: 1054–1060.
- Cosio FG; Frankel WL; Pelletier RP; Pesavento TE; Henry ML; Ferguson RM. Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival. *Am J Kidney Dis* 1999 Oct; 34(4):731-8.
- Cosyns JP; Couchoud C; Pouteil-Noble C; Squifflet JP; Pirson Y. Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. *Clin Nephrol* 1998 Sep; 50(3):144-53.
- Coulter MH: high speed automatic blood cell counter and size analyzer: paper presented at National conference, Chicago, 1956.
- Courtney AE; McNamee PT; Nelson WE; Maxwell AP. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy. *Nephrol Dial Transplant*. 2006 Dec; 21(12):3550-4.
- Couser W: Recurrent glomerulonephritis in the renal allograft: Australia and New Zealand Dialysis and Transplant Registry: ANZ- update of selected areas. *Exp Clin Transplant* 3: 283–288, 2005.
- Crocker BP, Salomon DR. Pathology of the renal allograft. In: Tisher CC, Brenner BM, eds. *Renal Pathology with Clinical and Functional Correlations*. Lippincott, Philadelphia: 1989: 1518–1554.

- Dall'Amico R, Ghiggeri GM, Carraro M. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. *Am J Kid Dis* 1999; 34: 1048–1055.
- D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. *Semin Nephrol* 2004; 24:179-196.
- Danovitch GM, Cecka JM. Allocation of deceased donor kidneys: past, present, and future. *Am J Kidney Dis* 2003; 42: 882–90.
- Daskalakis N, Winn M: Focal and segmental glomerulosclerosis: Varying biologic mechanisms underlie a final histopathologic end point. *Semin Nephrol* 2006; 26: 89–94.
- de Fijter JW. The impact of age on rejection in kidney transplantation. *Drugs Aging*. 2005; 22(5):433-49.
- Delmonico F. Exchanging kidneys. *Advances in living-kidney transplantation*. *N Engl J Med* 2004; 350: 1812–14.
- Delmonico F, Council of the Transplantation Society: A report of the Amsterdam Forum on the Care of the Live Kidney Donor: data and medical guidelines. *Transplantation* 2005; 79(6) :2-53.
- Delmonico FL, Dew MA. Living donor kidney transplantation in a global environment. *Kidney Int*. 2007 Apr;71(7):608-14.
- Denton MD; Singh AK. Recurrent and de novo glomerulonephritis in the renal allograft. *Semin Nephrol* 2000 Mar;20(2):164-75.

- Diane M. Cibrik, Bruce Kaplan, Darrell A. Campbell and Herwig-Ulf Meier Kriesche, Renal Allograft Survival in Transplant Recipients with Focal Segmental Glomerulosclerosis *American Journal of Transplantation*; 2003; 3: 64–67.
- Dittrich E; Schmaldienst S; Soleiman A; Horl WH; Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. *Transpl Int* 2004 May; 17(4):215-20.
- Donadio JV; Grande JP. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. *Semin Nephrol.* 2004 May; 24(3):225-43.
- du Buf-Vereijken PW; Branten AJ; Wetzels JF. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. *Nephrol Dial Transplant* 2004 May; 19(5):1142-8.
- F. Carneiro-Roza, J.O. Medina-Pestana, G. Moscoso-Solorzano, M. Franco, K. Ozaki, and G. Mastroianni-Kirsztajn. Initial Response to Immunosuppressive and Renoprotective Treatment in Posttransplant Glomerulonephritis *Transplantation Proceedings* 2006; 38, 3491–3497.
- F. G. Cosio, J. M. Gloor, S. Sethi and M. D. Stegall *Transplant Glomerulopathy. American Journal of Transplantation* 2008; 8: 492–496.

- Feehaly J: Predicting prognosis in IgA nephropathy. *Am J Kidney Dis* 2001; 38:881-883.
- Fellström B, Jardine AG, Soveri I, Cole E, Neumayer HH, Maes B, Gimpelewicz C, Holdaas H; ALERT Study Group. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. *Am J Transplant*. 2005 Aug; 5(8):1986-91.
- Floege J: Recurrent glomerulonephritis following renal transplantation: an update. *Nephrol dial transplant*, 2003 18:1260.
- Floege J; Eitner F. Present and future therapy options in IgA-nephropathy. *J Nephrol*. 2005 Jul-Aug; 18(4):354-61.
- Flynn JT, Schulman SL, Dechadarevian JP, et al: Treatment of steroid resistant post-transplant nephrotic syndrome with cyclophosphamide in a child with congenital nephritic syndrome. *Pediatr nephrol*, 1992 6:553.
- Freese PM, Svalander CT, Molne J, Nyberg G. Renal allograft glomerulopathy and the value of immunohistochemistry. *Clin Nephrol* 2004; 62: 279.
- Gabriel M. Danovitch: handbook of kidney transplantation fifth edition, 2010.
- Gallon L; Perico N; Dimitrov BD; Winoto J; Remuzzi G; Leventhal J; Gaspari F; Kaufman D. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression

comparing sirolimus vs. MMF. *Am J Transplant.* 2006 Jul; 6(7):1617-23.

Gaston R: Current and evolving immunosuppressive regimens in kidney transplantation. *Am J Kidney Dis.* Feb 2006; 47: S3–S21.

Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. *Am J Transplant.* 2003 Dec; 3(12):1488-500.

Gephardt GN, Tubbs RR, Braun WE et al. Nephrotic range proteinuria with ‘minimal change glomerulopathy’ in human renal allografts: report of four cases. *Am J Kid Dis* 1988; 12:51–61.

Gerald Opelz, MD, Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany, personal communication, July 2006, American Society of Transplantation Annual Meeting, Boston, MA.

Gill JS, Tonelli M, Mix CH. The effect of maintenance immunosuppression medication on the change in kidney allograft function. *Kidney Int.* Feb 2004; 65(2):692-9.

Gjertson DW, Cecka JM. Living unrelated kidney transplantation. *Kidney Int* 2000; 58: 491–9.

Glasscock RJ, Feldman D, Reynolds ES: Human renal isografts: a clinical and pathologic analysis. *Medicine (Baltimore)* 1968; 47:411.

- Glicklich D; Matas AJ; Sablay LB; Senitzer D; Tellis VA; Soberman R; Veith FJ. Recurrent membranoproliferative glomerulonephritis type 1 in successive renal transplants. *Am J Nephrol* 1987;7(2):143-9.
- Gloor JM, Sethi S, Stegall MD et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. *Am J Transplant* 2007; 9: 2124-2132.
- Gobel J, Olbricht CJ, Offner G, et al: Kidney transplantation in Alport's syndrome: long-term outcome and allograft anti-GBM nephritis. *Clin nephrol* 1992; 38:299.
- Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. *Transplantation* 2003; 76:798-803.
- Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. *Transpl Int.* 2007 Jun;20(6):558-62.
- Habib R, Antignac C, Hinglais N, Gagnadoux M-F, Broyer M. Glomerular lesions in the transplanted kidney in children. *Am J Kidney Dis* 1987; 10: 198–207.
- Halloran PF, Hunsicker LG. Delayed graft function. *Am J Transplant* 2001; 1: 115–20.

- Hanevold CD, Greenbaum LA. Nephrotic syndrome after conversion to alternate day steroids in two children with a history of recurrent FSGS. *Pediatr Transplant*. 2003 Oct;7(5):395-9.
- Hariharan S, Adams M, Brennan D, Davis C, First M, Johnson C, Ouseph R, Peddi V, Pelz C, Roza A, Vincenti F, George V: Recurrent and de novo glomerular disease after renal transplantation: A report from Renal Allograft Disease Registry (RADR). *Transplantation* 1999; 68:635–641.
- Hariharan S, Johnson C, Bresnahan B, Taranto S, McIntosh M, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. *N Engl J Med* 2000; 342: 605–612.
- Hariharan S, Peddi VR, Savin VJ et al. Recurrent and de novo renal diseases after renal transplantation: a report from the renal allograft disease registry. *Am J Kid Dis* 1998; 31:928–931.
- Hayry P, Isoniemi H, Yilmaz S et al. Chronic allograft rejection. *Immunol Rev* 1993; 134: 33–81.
- Heering P; Braun N; Mullejans R; Ivens K; Zauner I; Funfstuck R; Keller F; Kramer BK; Schollmeyer P; Risler T; Grabensee B. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. *Am J Kidney Dis* 2004 Jan; 43(1):10-8.

- Heidet L, Gagnadoux ME, Beziau A, et al: Recurrence of de novo membranous glomerulonephritis on renal grafts. Clin nephrol 41:314, 1994.
- Heinergarg D, Tiderstorm G: determination of serum creatinine by direct colormetric metjod. Clin chem. Acta 1973; 43: 305-310.
- Helderman JH, Bennett WM, Cibrik DM, Kaufman DB, Klein A, Takemoto SK. Immunosuppression: practice and trends. Am J Transplant. 2003; 3 Suppl 4:41-52.
- Hogan SL; Muller KE; Jennette JC; Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995 Jun; 25(6):862-75).
- Horvat LD, Shariff SZ, Garg AX. Global trends in the rates of living kidney donation. Kidney Int. 2009 May; 75(10):1088-98.
- Hoyer JR, Vernier RI, Najarian JS et al. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972; 11: 344–448.
- Humar A, Ramcharan T, Kandaswamy RJ, et al. Risk factors for slow graft function after kidney transplants: a multi-variate analysis. Clin Transplant 2002; 16: 425–9.
- Humar, A, Payne, WD, Sutherland, DE, Matas, AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000; 69:235.

- Ibrahim H, Rogers T, Casingal V: Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol. *Transplantation* 2006; 81: 214–219.
- Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, Gross CR, Matas AJ. Long-term consequences of kidney donation. *N Engl J Med*. 2009 Jan 29; 360(5):522-3.
- Ikezumi Y, Hurst L, Atkins RC, Nikolic-Paterson DJ. Macrophage-mediated renal injury is dependent on signaling via the JNK pathway. *J Am Soc Nephrol*. 2004 Jul; 15(7):1775-84.
- Ingulli E, Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis post-transplantation in 42 allografts in children—a single-center experience. *Transplantation* 1991; 51: 401–405
- Ismail-Allouch M, Burke G, Nery J et al. Rapidly progressive focal segmental glomerulosclerosis occurring in a living related kidney transplant donor. Case report and review of 21 cases of kidney transplants for primary FSGS. *Transplant Proc* 1993; 25: 2176–2177.
- Jais JP; Knebelmann B; Giatras I; De Marchi M; Rizzoni G; Renieri A; Weber M; Gross O; Netzer KO; Flinter F; Pirson Y; Verellen C; Wieslander J; Persson U; Tryggvason K; Martin P; Hertz JM; Schroder C; Sanak M; Krejcova S; Carvalho MF; Saus J; Antignac C; Smeets H; Gubler MC. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. *J Am Soc Nephrol* 2000 Apr; 11(4):649-57.

- Jha V; Ganguli A; Saha TK; Kohli HS; Sud K; Gupta KL; Joshi K; Sakhuja V. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. *J Am Soc Nephrol*. 2007 Jun; 18(6):1899-904.
- Johnston A; He X; Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. *Transplantation*. 2006 Dec 15; 82(11):1413-8.
- Jones JW, saadat-lajevardi S, lee t. an immunopassay for measurement of sirolimus. *Clin ther* 2000; 22:B49-61.
- Jordan SC, Vo A, Tyan D, Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. *Trans Am Clin Climatol Assoc*. 2006;117:199-211
- Josep M. Cruzadoa, Marta Carrerab, Joan Torrasa and Josep M. Grinyo. Hepatitis C Virus Infection and de Novo Glomerular Lesions in Renal Allografts. *American Journal of Transplantation* 2001; 1: 171±178.
- Josephson MA; Spargo B; Hollandsworth D; Thistlethwaite JR. The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review. *Am J Kidney Dis* 1994 Nov; 24(5):873-8.

- Kahan B, Camardo J. Rapamycin: clinical results and future opportunities. *Transplantation* 2001; 72:1181-1193.
- Kahan, B. D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. *Lancet* 2000; 356, 194–202.
- Kashtan CE: Alport syndrome: Renal transplantation and donor selection. *Ren fail* 2000; 22:765.
- Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR. The evaluation of renal transplantation candidates: clinical practice guidelines. *Am J Transplant.* 2001; 1: 23-95.
- Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, Rush D. Long-term deterioration of kidney allograft function. *Am J Transplant.* 2005 Jun;5(6):1405-14
- Keown P. Improving quality of life. The new target for transplantation. *Transplantation* 2001; 72 (Suppl 12): S67–74.
- Kershaw DB, Sedman AB, Kelsch RC, Bunchman TE. Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. *Clin Transplant* 1994; 8: 546–549.
- Kibert S, Schwartz MM, Lewis E. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. *Am J Kidney Dis* 1994; 23: 773–781.

- Kim SJ, Schaubel DE, Jeffery JR, Fenton SS. Centre-specific variation in renal transplant outcomes in Canada. *Nephrol Dial Transplant*. 2004 Jul; 19(7):1856-61.
- Kim YS; Moon JI; Jeong HJ; Kim MS; Kim SI; Choi KH; Lee HY; Han DS; Park K. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. *Transplantation* 2001 Jan 27; 71(2):233-8.
- Kirk AD, Hale DA, Mannon RB and Kleiner DE: Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody Alemtuzumab (Campath 1H). *Transplantation* 2003; (7691): 120-129.
- Korbet SM. Treatment of primary focal segmental glomerulosclerosis. *Kidney Int* 2002 Dec; 62(6):2301-10.
- Kowalewska J; Yuan S; Sustento-Reodica N; Nicosia RF; Smith KD; Davis CL; Alpers CE. IgA nephropathy with crescents in kidney transplant recipients. *Am J Kidney Dis* 2005 Jan; 45(1):167-75.
- Land W. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. *Transplantation* 2005; 79: 505–14.
- Lane PH, Schnaper HW, Vernier RL, et al: Steroid-dependant nephrotic syndrome following renal transplantation for congenital nephrotic syndrome. *Pediatr nephrol* , 1991;5:300.

- Letavernier E, Bruneval P, Mandet C, VanHuyen J, Peraldi M, Helal I, Noel L, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis de novo. *Clin J Am Soc Nephrol* 2: 326–333, 2007.
- Lien YH; Scott K. Long-term cyclophosphamide treatment for recurrent type I membranoproliferative glomerulonephritis after transplantation. *Am J Kidney Dis* 2000 Mar; 35(3):539-43.
- Little MA; Dupont P; Campbell E; Dorman A; Walshe JJ. Severity of primary MPGN determines renal survival and post-transplantation recurrence risk. *Kidney Int.* 2006 Feb; 69(3):504-11.
- Macdonald, A. S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. *Transplantation* 2001; 71, 271–280.
- Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. *Transplantation* 2003; 76:597-602.
- Marks WH, Wagner D, Pearson TC, et al. Organ donation and utilization, 1995-2004: entering the collaborative era. *Am J Transplantation* 2006; 6: 1101-1110.

- Mason, PD. Minimal change disease and primary focal segmental glomerulosclerosis. In: Comprehensive Clinical Nephrology, 3rd ed, Johnson R, J Feehally, Richard J Johnson, Elsevier Philadelphia 2007.
- Matalon A, Markowitz GS, Joseph RE, Cohen DJ, Saal SD, Kaplan B, D'Agati VD, Appel GB. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol. 2001 Oct;56(4):271-8.
- Matas A: Recurrent disease after kidney transplantation: It is time to unite to address this problem! Am J Transplant 2006; 6: 2527–2528.
- Matas AJ, Gillingham KJ, Humor A et al.; Immunologic and non-immunologic factors: different risks for cadaver and living donor transplantation. Transplantation 2000; 69:54.
- Matas AJ, Lawson W, McHugh L, et al. Employment patterns after successful kidney transplantation. Transplantation 1996; 61: 729–33
- Matsumoto H; Nakao T; Okada T; Nagaoka Y; Shino T; Yoshino M; Hidaka H. Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin Nephrol. 2001 Feb; 55(2):143-8.
- McLean RH; Geiger H; Burke B; Simmons R; Najarian J; Vernier RL; Michael AF. Recurrence of membranoproliferative glomerulonephritis following kidney transplantation. Serum

complement component studies. *Am J Med* 1976 Jan; 60(1):60-72.

Meehan SM; Pascual M; Williams WW; Tolkoff-Rubin N; Delmonico FL; Cosimi AB; Colvin RB SO: De novo collapsing glomerulopathy in renal allografts. *Transplantation* 1998 May 15; 65 (9):1192-7.

Meier-Kriesche, HU, Schold, JD, Srinivas, TR, Kaplan, B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. *Am J Transplant* 2004; 4:378.

Meyrier A. Treatment of idiopathic nephrosis by immunophilin modulation. *Nephrol Dial Transplant*. 2003 Aug; 18 Suppl 6: 79-86

Meyrier, A. Nephrotic focal segmental glomerulosclerosis in 2004: an update. *Nephrol Dial Transplant* 2004; 19:2437.

Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. *Transplantation* 2003; 75(5):657-662.

Midtvedt K; Hjelmessaeth J; Hartmann A; Lund K; Paulsen D; Egeland T; Jenssen T. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. *J Am Soc Nephrol* 2004 Dec; 15(12):3233-9.

Miller L. Cardiovascular toxicities of immunosuppressive agents. *Transplantation* 2002; 2:807-902.

- Mizutani K, Terasaki P, Hamdani E. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. *Am J Transplantation* 2007; 7:1027-1031.
- Molina MG, Seron D, del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. *Transplantation* 2004; 77:215.
- Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. *JAMA* 2005; 294: 1655–63.
- Morales JM, Pascual-Capdevila J, Campistol JM, et al: Membranous glomerulonephritis associated with hepatitis C virus in renal transplant patients. *Transplantation* 63:1634, 1997.
- Morales JM; Martinez MA; Munoz de Bustillo E; Munoz MA; Gota R; Usera G. Recurrent type III membranoproliferative glomerulonephritis after kidney transplantation. *Transplantation* 1997 Apr 27; 63(8):1186-8.
- Muczynski KA. Plasmapheresis maintained renal function in an allograft with recurrent membranoproliferative glomerulonephritis type I. *Am J Nephrol* 1995; 15(5):446-9.
- Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. *N Engl J Med* 1984; 311: 699–705.

- Naesens M, Kuypers D, Sarwal M. Calcineurin Inhibitor Nephrotoxicity. Clin J Am Soc Nephro 2009; 4:481-508.
- Nakayama M; Katafuchi R; Yanase T; Ikeda K; Tanaka H; Fujimi S: Steroid responsiveness and frequency of relapse in adult-onset minimal change nephrotic syndrome. Am J Kidney Dis 2002 Mar; 39(3):503-12).
- Nangaku M, Couser WG: Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol. Sep 2005; 9(3):183-91.
- Neumayer HH, Huls S, Schreiber M, et al: Kidney transplantation from pediatric donors: risk versus benefit. Clin nephrol 41:94, 1994.
- Noël LH, Gubler MC. Histological classification of chronic glomerular diseases. Rev Prat. 2003 Nov 30; 53(18):2005-12.
- Norman DJ, Kahanal, Stuart Jr, FP et al.: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993, 55: 44-50.
- Ohta T, Kawaguchi H, Hattori M et al. Effect of pre- and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 2001; 71: 628–633.
- Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal deceased donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589–97.

- Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for renal allograft survival. *Transplantation* 1997; 63: 968–72.
- Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. *Transplantation* 1995 Dec 15; 60(11):1220-4.
- Opelz G; Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet* 2005; 365: 1570–6.
- Opelz G; Dohler B. Cyclosporine and long-term kidney graft survival. *Transplantation* 2001 Oct 15;72(7):1267-73.
- Otukesh H, Hoseini R, Fereshtehnejad SM, Behzadi AH, Chalian M, Jazayeri M, Chalian H, Javadi R. Outcome of living donor renal allograft survival in children with focal segmental glomerulosclerosis. *Pediatr Transplant*. 2009 Feb; 13(1):39-43.
- Parasuraman R, Yee J, Karthikeyan V, del Busto R: Infectious complications in renal transplant recipients. *Am j transplantation* 2006: 2527–2528.
- Park K, Lee JH, Huh KH, et al. Exchange living-donor kidney transplantation: diminution of donor organ shortage. *Transplant Proc* 2004; 36: 2949–51.

- Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. *Transplantation*. 2003 Jan 15; 75(1):43-9.
- Pesce AJ, Schroeder TJ, First MR. An evaluation of cyclosporine monitoring by non selective fluorescence polarization immunoassay. *Transplantation Proceedings* 1990; 22: 1171-1174.
- Peter J. Morris: kidney transplantation: principles and practice. 6th edition, 2008.
- Philibert D; Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? *Nat Clin Pract Nephrol*. 2008 Oct; 4(10):550-9.
- Ponticelli C, Villa M, Cesana B, et al. Risk factors for late kidney allograft failure. *Kidney Int* 2002; 62: 1848–52.
- Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A. Risk factors for late kidney allograft failure. *Kidney Int*. 2002 Nov; 62(5):1848-54.
- Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide

in idiopathic membranous nephropathy. *J Am Soc Nephrol* 1998 Mar; 9(3):444-50.

Ponticelli C; Minetti L; Di Palo FQ; Vegeto A; Belli L; Corbetta G; Tarantino A; Civati G. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. *Transplantation* 1988 May; 45(5):908-13.

Ponticelli C; Zucchelli P; Passerini P; Cesana B; Locatelli F; Pasquali S; Sasdelli M; Redaelli B; Grassi C; Pozzi C. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. *Kidney Int* 1995 Nov; 48(5):1600-4.

Port FK, Merino RM, Goodrich NP, Wolfe RA. Recent trends and results for organ donation and transplantation in the United States, 2005. *Is J Transplant* 2006; 6: 1095–100.

Praga M, Borstein B, Andres A. Nephrotic proteinuria without hypoalbuminemia: Clinical characteristics and response to angiotensin-converting enzyme inhibition. *Am J Kidney Dis* 1991; 17:330.

Prommool S, Jhangri GS, Cockfield SM, Halloran PF. Time dependency of factors affecting renal allograft survival. *J Am Soc Nephrol*. 2000 Mar; 11(3):565-73.

- Quiroga I, McShane P, Koo DD, Gray D, Friend PJ, Fuggle S, Darby C. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. *Nephrol Dial Transplant*. 2006 Jun;21(6):1689-96.
- Racusen LC, Solez K, Colvin R. Fibrosis and atrophy in the renal allograft. Interim report and new directions. *Am J Transplant* 2002; 2: 203–206.
- Racusen LC, Solez K, Colvin R. Fibrosis and atrophy in the renal allograft. Interim report and new directions. *Am J Transplant* 2003; 2: 203–206.
- Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y, et al.: The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999; 55:713-723.
- Raimund H. Pichler, Stuart J. Shankland. Glomerular diseases. In American college of physician (ACP Medicine), 3rd edition (2007 edition), Dale, David C, Federman, Daniel D.
- Ramos EL, Tisher CC: Recurrent diseases in the kidney transplant. *Am j kidney dis*, 1994 24:142.
- Requia~o-Moura LR, Moscoso-Solorzano GT, Franco MF, Ozaki KS, Pacheco-Silva A, Kirsztajn GM, Ca~mara NOS: Prognostic

factors associated with poor graft outcomes in renal recipients with post-transplant glomerulonephritis. *Clin Transplant* 2007; 21: 363–370.

Rhen T; Cidlowski JA. Anti-inflammatory action of glucocorticoids--new mechanisms for old drugs. *N Engl J Med* 2005 Oct 20; 353(16):1711-23.

Rivera F, Lopez-Gomez JM, Perez-Garcia R: Clinicopathologic correlations of renal pathology in Spain. *Kidney Int* 2004; 66:898.

Rizzoni G, Ehrich JHH, Bunner FP et al. Combined report on regular dialysis and transplantation of children in Europe, 1990. *Nephrol Dial Transplant* 1991; 6: 31–42.

Rodriguez-Iturbe B; Musser JM. The current state of poststreptococcal glomerulonephritis. *J Am Soc Nephrol*. 2008 Oct; 19(10):1855-64.

Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. *J Am Soc Nephrol*. 2005 May;16(5):1205-13.

Roth D; Cirocco R; Zucker K; Ruiz P; Viciano A; Burke G; Carreno M; Esquenazi V; Miller J. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. *Transplantation* 1995 Jun 27; 59(12):1676-82.

- Salant, D, Dember, LM. Minimal change disease. In: Therapy in Nephrology and Hypertension, 2d ed, Brady, HR, Wilcox, CS (Eds), Saunders, Philadelphia, 2003.
- Salvadori M, Rosati A, Bock A, Chapman J, Dussol B, Fritsche L, Kliem V, Lebranchu Y, Oppenheimer F, Pohanka E, Tufveson G, Bertoni E. Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. *Transplantation*. 2006 Jan 27; 81(2):202-6.
- Sarwal MM. Chipping into the human genome: novel insights for transplantation. *Immunol Rev* 2006; 210:135-155.
- Savin V, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. *N Engl J Med* 1996; 334: 878–883.
- Schreuder GM, Hurley CK, Marsh SG, Lau M, Fernandez-Vina M, Noreen HJ, Setterholm M, Maiers M. The HLA Dictionary 2004: a summary of HLA-A, -B, -C, -DRB1/3/4/5 and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. *Int J Immunogenet*. 2005 Feb; 32(1):19-69.
- Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.. *Am J Kidney Dis* 1989 Nov;14(5 Suppl 2):14-8.
- Schwarz A; Krause PH; Offermann G; Keller F. Impact of de novo membranous glomerulonephritis on the clinical course after

kidney transplantation. Transplantation 1994 Sep 27; 58(6):650-4.

Segev DL, Simpkins RA, Hartman EC, et al. ABO incompatible high-titer transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5: 2750–5.

Senguttuvan P, Cameron JS, Hartley RB et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990; 4: 21–28

Sharma M, Sharma R, McCarthy ET, Savin VJ. ‘The FSGS Factor’: enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999; 10: 552–561.

Sherif AM; Refaie AF; Sobh MA; Mohamed NA; Sheashaa HA; Ghoneim MA. Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis 2003 Aug; 42(2):370-5.

Shihab FS; Waid TH; Conti DJ; Yang H; Holman MJ; Mulloy LC; Henning AK; Holman J Jr; First MR. Conversion From Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Allograft Failure: 60-Month Results of the CRAF Study. Transplantation 2008 May 15; 85(9):1261-1269.

Shimmura H, Tanabe K, Ishida H, et al. Lack of correlation between results of ABO-incompatible living kidney transplants and anti-

- ABO blood type titers under current immunosuppression. Transplantation 2005; 80: 985–8.
- Siddqi, N, Hariharan, S, Danovitch, G. Evaluation and Preparation of Renal Transplant Candidates. Handbook of Kidney Transplantation, Fourth Ed., Lippincott Williams Wilkins, Philadelphia 2005.
- Sis B, Campbell PM, Mueller T et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743-1752.
- Solez K, Colvin RB, Racusen LC. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy. Am J Transplant 2007; 7:518-526.
- Spital A. Living kidney donors: still a valuable resource. Curr Opin Organ Transplant 1998; 3: 205–11.
- Srinivas TR; Schold JD; Guerra G; Eagan A; Bucci CM; Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007 Mar; 7(3):586-94.
- Srivasta RN, Kalia A, Travis LB, Diven SC, Gugliuzza KK, Rajaraman S. Prompt remission of post-renal transplant nephrotic syndrome with high-dose cyclosporine. Pediatr Nephrol 1994; 8: 94–95.
- Steinbrook R. Public solicitation of organ donors. N Engl J Med 2005; 353: 441–4.

- Stephanian E, Matas AJ, Mauer SM. Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis. *Transplantation* 1992; 53: 755–757.
- Stirling CM, Mathieson P, Bolton-Jones JM, et al: Treatment and outcome of adults with primary focal segmental glomerulosclerosis in five UK renal units. *Q J Med* 2005; 98:443-449.
- Striegel JE, Sibley RK, Fryd DS, Mauer M. Recurrence of focal segmental sclerosis in children following renal transplantation. *Kidney Int* 1986; 19: S44–S50.
- Strippoli GF; Manno C; Schena FP. An "evidence-based" survey of therapeutic options for IgA nephropathy: assessment and criticism. *Am J Kidney Dis* 2003 Jun; 41(6):1129-39.
- Swaminathan S, Lager D, Qian X, Stegall M, Larson T, Griffin M: Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. *Nephrol Dial Transplant* 2006; 21: 2607–2614.
- Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. *Transplantation* 1998; 65: 1533–42.
- Takahashi K, Takahara S, Uchida K, et al. Successful results after 5 years of tacrolimus therapy in ABO-incompatible kidney transplantation in Japan. *Transplant Proc* 2005; 37: 1800–3.

- Tejani A, Nicastrì AD, Sen D, Chen CK, Phadke K, Adamson O, Butt KM. Long-term evaluation of children with nephritic syndrome and focal segmental glomerular sclerosis. *Nephron* 1983; 35: 225–231.
- Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. *Transplantation* 2005 Nov 15; 80(9):1194-7.
- Tilney NL. Transplantation between identical twins: a review. *World J Surg* 1986; 10: 381–5.
- Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. *Kidney Int.* Sep 2004; 66(3):1199-205.
- Troyanov S; Wall CA; Miller JA; Scholey JW; Cattran DC. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. *J Am Soc Nephrol* 2005 Apr; 16(4):1061-8.
- Truong L; Gelfand J; D'Agati V; Tomaszewski J; Appel G; Hardy M; Pirani CL. De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature. *Am J Kidney Dis* 1989 Aug; 14(2):131-44.
- Tullius SG, Reutzel-Selke A, Bachmann U, Jurisch A, Nieminen-Kelhä M, Pratschke J, Jonas S, Steinmüller T, Volk HD, Neuhaus P. Influence of recipient and donor age on long-term renal allograft function in an experimental model. *Transplant Proc.* 2001 Nov-Dec;33(7-8):3345-6.

- Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. *Transplantation* 2003; 76: 730–1.
- US Renal Data System: Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases 2006.
- Van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. *Clin Sci (Lond)*. 2004 Aug; 107(2):125-36.
- van Hest RM; Mathot RA; Pescovitz MD; Gordon R; Mamelok RD; van Gelder T. Explaining variability in mycophenolic Acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic Acid in renal transplant recipients. *J Am Soc Nephrol*. 2006 Mar; 17(3):871-80.
- Vega O, Cárdenas G, Correa-Rotter R, Alberú J, Morales-Buenrostro LE. Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. *Rev Invest Clin*. 2008 Mar-Apr; 60(2):82-6.
- Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. *Am J Transplant*. 2005 Jun; 5(6):1179-85.

- Waldman M; Crew RJ; Valeri A; Busch J; Stokes B; Markowitz G; D'Agati V; Appel G. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. *Clin J Am Soc Nephrol*. 2007 May; 2(3):445-53.
- Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonist for renal transplant recipients: a meta-analysis of randomized trials. *Transplantation* 2004; 77:166-176.
- Webster AC; Woodroffe RC; Taylor RS; Chapman JR; Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. *BMJ* 2005 Oct 8;331(7520):810.
- Whiting JF, Golconda M, Smith R, et al. Economic cost of expanded criteria donors in renal transplantation. *Transplantation* 1998; 65: 204–7.
- William A. Golgert, Gerald B. Appel, and Sundaram Hariharan Recurrent Glomerulonephritis after Renal Transplantation:An Unsolved Problem. *Clin J Am Soc Nephrol* 2008; (3): 800-807.
- Winn MP, Alkhunaizi AM, Bennett WM et al. Focal segmental glomerulosclerosis: A need for caution in live-related renal transplantation. *Am J Kidney Dis* 1999; 33: 970–974.
- Wolfe RA, Ashby VB, Milford EL. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. *N Engl J Med* 1999; 341: 1725–30.

- Woodward RS; Kutinova A; Schnitzler MA; Brennan DC. Renal graft survival and calcineurin inhibitor. *Transplantation* 2005 Sep 15; 80(5):629-33.
- Woolley AC, Rosenberg ME, Burke BA, et al: De novo focal gs after kidney transplantation. *Am j med* 1988; 84:310.
- Worawon Chailimpamontree, Svetlana Dmitrienko, Guiyun Li, Robert Balshaw, Alexander Magil, R. Jean Shapiro, David Landsberg, John Gill, Paul A. Keown: Probability, Predictors, and Prognosis of Posttransplantation Glomerulonephritis. *J Am Soc Nephrol* 2009; 20: 843–851.
- Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. *Am J Transplant*. 2008 Jan; 8(1):222-7.
- Yamamoto I, Horita S, Takahashi T et al. Glomerular expression of plasmalemmal vesicle-associated protein-1 in patients with transplant glomerulopathy. *Am J Transplant* 2007; 7: 1954-1960.
- Zachary AA, Montgomery RA, Ratner LE. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. *Transplantation* 2003; 76:1519-1525.
- Zeman M, Campbell P, Bain VG. Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. *Can J Gastroenterol*. 2006 Jun; 20(6):427-31.